Literature DB >> 2495052

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.

M Youle1, J Clarbour, C Farthing, M Connolly, D Hawkins, R Staughton, B Gazzard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2495052      PMCID： PMC1835649          DOI： 10.1136/bmj.298.6671.432

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Significant response of oral aphthosis to thalidomide treatment.

Authors:  D Grinspan
Journal:  J Am Acad Dermatol       Date:  1985-01       Impact factor: 11.527

2.  Oral manifestations in patients with AIDS or AIDS-related complex.

Authors:  C E Barr; J P Torosian
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

3.  Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis.

Authors:  H Torras; M Lecha; J M Mascaro
Journal:  Arch Dermatol       Date:  1982-11

4.  Thalidomide--effect on T cell subsets as a possible mechanism of action.

Authors:  B Moncada; M L Baranda; R González-Amaro; R Urbina; C E Loredo
Journal:  Int J Lepr Other Mycobact Dis       Date:  1985-06
  4 in total
  11 in total

Review 1.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

3.  New roles for thalidomide.

Authors:  R J Powell
Journal:  BMJ       Date:  1996-08-17

4.  Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.

Authors:  S M Naum; P J Molloy; R J Kania; J McGarr; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

5.  Thalidomide--the way forward.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

6.  Thalidomide-induced neuropathy and genetic differences in drug metabolism.

Authors:  C C Harland; G B Steventon; J R Marsden
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 7.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 8.  Thalidomide: rationale for renewed use in immunological disorders.

Authors:  U Schuler; G Ehninger
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

9.  Thalidomide: an emerging drug in oral mucosal lesions.

Authors:  K Mubeen; M Ahmed Siddiq; V R Jigna
Journal:  Clin J Gastroenterol       Date:  2009-06-02

10.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Authors:  J B Bartlett; A Michael; I A Clarke; K Dredge; S Nicholson; H Kristeleit; A Polychronis; H Pandha; G W Muller; D I Stirling; J Zeldis; A G Dalgleish
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.